Safety and efficacy of upadacitinib monotherapy in adolescents and adults with moderate-to-severe atopic dermatitis: Results from two pivotal, phase III, randomized, double-blinded, monotherapy, placebo-controlled studies (Measure Up 1 and Measure Up 2)

Authors
Category Primary study
ConferenceBritish Journal of Dermatology
Year 2021
This article has no abstract
Epistemonikos ID: 7b3f444b9410ed87c7f1928b9a26c98b10aadd7e
First added on: Apr 30, 2026